Department of Central Laboratory, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Reproductive Medicine Center, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
RNA Biol. 2023 Jan;20(1):207-218. doi: 10.1080/15476286.2023.2213915.
Updates in whole genome sequencing technologies have revealed various RNA modifications in cancer, among which RNA methylation is a frequent posttranscriptional modification. RNA methylation is essential for regulating biological processes such as RNA transcription, splicing, structure, stability, and translation. Its dysfunction is strongly associated with the development of human malignancies. Research advances with respect to the regulatory role of RNA modifications in ovarian cancer include N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), and N7-methylguanosine (m7G). Numerous studies have demonstrated that epigenetic modifications of RNA can influence the progression and metastasis of ovarian cancer and may provide excellent targets for cancer therapy. This review highlights advances in research on RNA methylation modifications and ovarian cancer prognosis, carcinogenesis, and resistance, which could provide a theoretical foundation for designing therapeutic strategies for ovarian cancer based on RNA methylation modifications.
全基因组测序技术的更新揭示了癌症中各种 RNA 修饰,其中 RNA 甲基化是一种常见的转录后修饰。RNA 甲基化对于调节 RNA 转录、剪接、结构、稳定性和翻译等生物过程至关重要。其功能障碍与人类恶性肿瘤的发展密切相关。关于 RNA 修饰在卵巢癌中调控作用的研究进展包括 N6-甲基腺苷(m6A)、5-甲基胞嘧啶(m5C)、N1-甲基腺苷(m1A)和 N7-甲基鸟嘌呤(m7G)。大量研究表明,RNA 的表观遗传修饰可以影响卵巢癌的进展和转移,并且可能为癌症治疗提供极好的靶点。本综述重点介绍了 RNA 甲基化修饰与卵巢癌预后、致癌、耐药性的研究进展,为基于 RNA 甲基化修饰设计卵巢癌治疗策略提供了理论基础。